Core Insights - Artelo Biosciences, Inc. presented new data at the British Pain Conference, highlighting the therapeutic potential of Fatty Acid Binding Protein (FABP) inhibitors for treating osteoarthritis (OA) pain [1][2] - The lead FABP5 inhibitor, ART26.12, demonstrated analgesic effects comparable to naproxen in animal studies, with sustained effects over 28 days [4][3] - OA affects approximately 606.9 million people globally, with over 32 million in the U.S., leading to significant mobility loss and reduced quality of life [5] Company Overview - Artelo Biosciences is a clinical-stage pharmaceutical company focused on developing therapeutics that modulate lipid-signaling pathways for various conditions, including cancer, pain, and inflammation [7] - The company is advancing a portfolio of product candidates aimed at addressing unmet medical needs across multiple diseases [7] - ART26.12 is currently undergoing human trials, with initial clinical development targeting chemotherapy-induced peripheral neuropathy (CIPN) [6]